Novo Nordisk’s stock is experiencing a steep drop following major clinical setbacks and intensifying competitive pressure in the weight-loss-drug market.
Results from the EVOKE and EVOKE+ trials showed no significant advantage over a placebo, erasing hopes that the company could expand its diabetes and obesity franchise into neurodegenerative disorders.
“While treatment with semaglutide resulted in improvement of Alzheimer’s disease–related biomarkers in both trials, this did not translate into a delay of disease progression,” the company said.
